<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />

<meta name="author" content="Tushar Patni" />


<title>gsMAMS</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>




<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">gsMAMS</h1>
<h4 class="author">Tushar Patni</h4>



<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">1234</span>)</span>
<span id="cb1-2"><a href="#cb1-2" tabindex="-1"></a><span class="fu">library</span>(gsMAMS)</span></code></pre></div>
<p>We will demonstrate the use of <code>gsMAMS</code> package and
provide a detailed example for each type of outcome explaining the
output and every argument of all the functions.</p>
<div id="continuous-outcome" class="section level2">
<h2>Continuous outcome</h2>
<p>For the continuous outcome, we will consider TAILoR trial, which is a
phase II trial, and it compares three doses of telmisartan (20, 40,
80mg) with no intervention (control) for the reduction of insulin
resistance in human immunodeficiency virus-positive patients receiving
combination antiretroviral therapy. The primary outcome measure is a
reduction in mean homeostasis model assessment of insulin resistance
(HOMA-IR) score at 24 weeks. The standardized desirable and minimal
effect sizes for efficacy are set as <span class="math inline">\(\delta^{(1)}\)</span> = 0.545 for 80mg group and
<span class="math inline">\(\delta^{(0)}\)</span> = 0.178 for 20 and 40
mg groups, respectively, for the trial design. The sample size
calculation is based on a one-sided type I error of 5% and a power of
90%. Based on the trial characteristics, we will design the trial for a
two-stage design. The design parameters of the trial can be calculated
using the design_cont function and the arguments in the function
correspond to standardized effect size in ineffective arm(delta0} and
effective arm(delta1), type I error(alpha), type II error(beta), total
number of treatment arms(K) and the information time (0.5, 1) is denoted
by frac argument in the function.</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" tabindex="-1"></a><span class="fu">design_cont</span>(<span class="at">delta0 =</span> <span class="fl">0.178</span>,<span class="at">delta1 =</span> <span class="fl">0.545</span>,<span class="at">alpha =</span> <span class="fl">0.05</span>,<span class="at">beta =</span> <span class="fl">0.1</span>,<span class="at">k=</span><span class="dv">3</span>,</span>
<span id="cb2-2"><a href="#cb2-2" tabindex="-1"></a><span class="at">frac =</span> <span class="fu">c</span>(<span class="fl">0.5</span>,<span class="dv">1</span>))</span>
<span id="cb2-3"><a href="#cb2-3" tabindex="-1"></a><span class="co">#&gt; $`Sample size`</span></span>
<span id="cb2-4"><a href="#cb2-4" tabindex="-1"></a><span class="co">#&gt;                                            Stage 1 Stage 2</span></span>
<span id="cb2-5"><a href="#cb2-5" tabindex="-1"></a><span class="co">#&gt; Cumulative sample size for treatment group      40      79</span></span>
<span id="cb2-6"><a href="#cb2-6" tabindex="-1"></a><span class="co">#&gt; Cumulative sample size for control group        40      79</span></span>
<span id="cb2-7"><a href="#cb2-7" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb2-8"><a href="#cb2-8" tabindex="-1"></a><span class="co">#&gt; $`Maximum total sample size for the trial`</span></span>
<span id="cb2-9"><a href="#cb2-9" tabindex="-1"></a><span class="co">#&gt; [1] 316</span></span>
<span id="cb2-10"><a href="#cb2-10" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb2-11"><a href="#cb2-11" tabindex="-1"></a><span class="co">#&gt; $`Boundary values`</span></span>
<span id="cb2-12"><a href="#cb2-12" tabindex="-1"></a><span class="co">#&gt;             Stage 1 Stage 2</span></span>
<span id="cb2-13"><a href="#cb2-13" tabindex="-1"></a><span class="co">#&gt; Lower bound   0.006   2.062</span></span>
<span id="cb2-14"><a href="#cb2-14" tabindex="-1"></a><span class="co">#&gt; Upper bound   2.910   2.062</span></span></code></pre></div>
<p>The design output shows the cumulative sample size for treatment and
control groups at each stage. The SCPRT lower and upper boundaries are
(0.006, 2.062) and (2.91, 2.062) respectively. Based on the design
parameters, the first interim analysis can be conducted after the
enrollment of 40 patients in the control arm. If the test statistic
<span class="math inline">\(Z_{k,l}&lt;0.006\)</span>, the <span class="math inline">\(k_{th}\)</span> arm is rejected for futility at
<span class="math inline">\(1^{st}\)</span> stage and the trial
continues with the remaining treatment arms and the control. If the test
statistic 0.006 <span class="math inline">\(\le\)</span> <span class="math inline">\(Z_{k,l}\)</span> <span class="math inline">\(\le\)</span> 2.91 for <span class="math inline">\(k\)</span>=1,2,3 then the trial continues to the
next stage and 39 patients are further enrolled per arm. If <span class="math inline">\(Z_{k,1} &gt;2.91\)</span> for some <span class="math inline">\(k\)</span>, the trial is terminated and the arm
with maximum value of <span class="math inline">\(Z_{k,1}\)</span>,
<span class="math inline">\(k\)</span>=1,2,3 would be recommend for
further study.</p>
<p>For FWER and Stagewise FWER:</p>
<p>The operating characteristics of the trial can be generated using the
op_power_cont and op_fwer_cont functions for power under alternative
hypothesis and FWER under global null hypothesis respectively. Most of
the arguments in the function are similar to size and SCPRT functions
with the exception of number of simulations(nsim) and seed
number(seed).</p>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" tabindex="-1"></a><span class="fu">op_fwer_cont</span>(<span class="at">alpha=</span><span class="fl">0.05</span>,<span class="at">beta=</span><span class="fl">0.1</span>,<span class="at">p=</span><span class="dv">3</span>,<span class="at">frac=</span><span class="fu">c</span>(<span class="fl">0.5</span>,<span class="dv">1</span>),<span class="at">delta0=</span><span class="fl">0.178</span>,</span>
<span id="cb3-2"><a href="#cb3-2" tabindex="-1"></a><span class="at">delta1=</span><span class="fl">0.545</span>,<span class="at">nsim=</span><span class="dv">10000</span>,<span class="at">seed=</span><span class="dv">10</span>)</span>
<span id="cb3-3"><a href="#cb3-3" tabindex="-1"></a><span class="co">#&gt; $FWER</span></span>
<span id="cb3-4"><a href="#cb3-4" tabindex="-1"></a><span class="co">#&gt; [1] 0.05</span></span>
<span id="cb3-5"><a href="#cb3-5" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb3-6"><a href="#cb3-6" tabindex="-1"></a><span class="co">#&gt; $`Stagewise FWER`</span></span>
<span id="cb3-7"><a href="#cb3-7" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb3-8"><a href="#cb3-8" tabindex="-1"></a><span class="co">#&gt; 0.0050 0.0466 </span></span>
<span id="cb3-9"><a href="#cb3-9" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb3-10"><a href="#cb3-10" tabindex="-1"></a><span class="co">#&gt; $`Stopping probability under null`</span></span>
<span id="cb3-11"><a href="#cb3-11" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb3-12"><a href="#cb3-12" tabindex="-1"></a><span class="co">#&gt; 0.2599 0.7401 </span></span>
<span id="cb3-13"><a href="#cb3-13" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb3-14"><a href="#cb3-14" tabindex="-1"></a><span class="co">#&gt; $`Probability of futility under null`</span></span>
<span id="cb3-15"><a href="#cb3-15" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb3-16"><a href="#cb3-16" tabindex="-1"></a><span class="co">#&gt; 0.2549 0.6949 </span></span>
<span id="cb3-17"><a href="#cb3-17" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb3-18"><a href="#cb3-18" tabindex="-1"></a><span class="co">#&gt; $`Average sample size used per arm under null`</span></span>
<span id="cb3-19"><a href="#cb3-19" tabindex="-1"></a><span class="co">#&gt; [1] 61.645</span></span></code></pre></div>
<p>Based on the simulation results, the type I error at the first
interim analysis is 0.5% and at the second interim analysis, it is
around 4.6%. Therefore, the overall type I error of the trial is close
to 5%. The sample size required for the trial was 79 patients per arm
but the trial used around an average of 62 subjects per arm. The
stopping probability(probability of stopping the trial either due to
futility or efficacy) should add up to 1 which is the case here and
since this is under null configuration, the probability of
futility(probability of stopping the trial when all the treatment arms
becomes futile in the trial) should be around 95% and it holds true in
this case.</p>
<p>For Power and Stagewise Power:</p>
<div class="sourceCode" id="cb4"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" tabindex="-1"></a><span class="fu">op_power_cont</span>(<span class="at">alpha=</span><span class="fl">0.05</span>,<span class="at">beta=</span><span class="fl">0.1</span>,<span class="at">p=</span><span class="dv">3</span>,<span class="at">frac=</span><span class="fu">c</span>(<span class="fl">0.5</span>,<span class="dv">1</span>),<span class="at">delta0=</span><span class="fl">0.178</span>,</span>
<span id="cb4-2"><a href="#cb4-2" tabindex="-1"></a><span class="at">delta1=</span><span class="fl">0.545</span>,<span class="at">nsim=</span><span class="dv">10000</span>,<span class="at">seed=</span><span class="dv">10</span>)</span>
<span id="cb4-3"><a href="#cb4-3" tabindex="-1"></a><span class="co">#&gt; $Power</span></span>
<span id="cb4-4"><a href="#cb4-4" tabindex="-1"></a><span class="co">#&gt; [1] 0.893</span></span>
<span id="cb4-5"><a href="#cb4-5" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb4-6"><a href="#cb4-6" tabindex="-1"></a><span class="co">#&gt; $`Stagewise Power`</span></span>
<span id="cb4-7"><a href="#cb4-7" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb4-8"><a href="#cb4-8" tabindex="-1"></a><span class="co">#&gt; 0.3126 0.5804 </span></span>
<span id="cb4-9"><a href="#cb4-9" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb4-10"><a href="#cb4-10" tabindex="-1"></a><span class="co">#&gt; $`Stopping probability under alternative`</span></span>
<span id="cb4-11"><a href="#cb4-11" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb4-12"><a href="#cb4-12" tabindex="-1"></a><span class="co">#&gt; 0.3258 0.6742 </span></span>
<span id="cb4-13"><a href="#cb4-13" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb4-14"><a href="#cb4-14" tabindex="-1"></a><span class="co">#&gt; $`Probability of futility under alternative`</span></span>
<span id="cb4-15"><a href="#cb4-15" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb4-16"><a href="#cb4-16" tabindex="-1"></a><span class="co">#&gt; 0.0035 0.0821 </span></span>
<span id="cb4-17"><a href="#cb4-17" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb4-18"><a href="#cb4-18" tabindex="-1"></a><span class="co">#&gt; $`Average sample size used per arm under alternative`</span></span>
<span id="cb4-19"><a href="#cb4-19" tabindex="-1"></a><span class="co">#&gt; [1] 62.652</span></span></code></pre></div>
<p>Based on the simulation results, the probability of success/power at
the first stage is 31.26% and at the second stage is around 58.04%.
Therefore, the overall power is approximately 90%. The sample size
required for the trial was 79 patients per arm but the trial used around
an average of 62 subjects per arm. The stopping probability should add
up to 1 which is the case here and under alternate configuration, the
probability of futility is approximately 8.5% which is less than 10%
type II error. The reason is that the type II error comes from both
failing to find any efficacious arm (futility) and finding the less
efficacious arm as the most efficacious arm. The latter part was not
included when the probability of futility was calculated.</p>
</div>
<div id="ordinal-outcome" class="section level2">
<h2>Ordinal Outcome</h2>
<p>For ordinal outcome, we will consider ASCLEPIOS trial, a phase II
trial for patients with stroke. The primary outcome response is the
patient’s Barthel index assessed 90 days after randomization. This is an
ordered categorical score ranging from 0 (vegetative state) to 100
(complete recovery) in steps of 5, and relates to activities of daily
living that the patient is able to undertake. Following the ASCLEPIOS
study, we group the outcome categories of the score into six larger
categories. We will consider the treatment worthwhile if the odds ratio
between the effective and control arms is 3.06 and we set the null odds
ratio to be 1.32 which is the odds ratio between the ineffective and
control arms.<br />
The sample size calculation is based on a one-sided FWER of 5% and a
power of 90%. Based on the trial characteristics, we will design the
trial for a three-stage design. The design parameters for a five-arm (K
= 4) trial can be calculated using design_ord function and the arguments
in the function correspond to probability of outcomes in control
group(prob), odds ratio of ineffective treatment group vs control(or0),
odds ratio of effective treatment group vs control(or) and the remaining
arguments are similar to the design_cont function for continuous
outcome.</p>
<div class="sourceCode" id="cb5"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb5-1"><a href="#cb5-1" tabindex="-1"></a><span class="fu">design_ord</span>(<span class="at">prob=</span><span class="fu">c</span>(<span class="fl">0.075</span>, <span class="fl">0.182</span>, <span class="fl">0.319</span>, <span class="fl">0.243</span>, <span class="fl">0.015</span>, <span class="fl">0.166</span>),<span class="at">or=</span><span class="fl">3.06</span>,</span>
<span id="cb5-2"><a href="#cb5-2" tabindex="-1"></a><span class="at">or0=</span><span class="fl">1.32</span>,<span class="at">alpha=</span><span class="fl">0.05</span>,<span class="at">beta=</span><span class="fl">0.1</span>,<span class="at">k=</span><span class="dv">4</span>,<span class="at">frac =</span> <span class="fu">c</span>(<span class="dv">1</span><span class="sc">/</span><span class="dv">3</span>,<span class="dv">2</span><span class="sc">/</span><span class="dv">3</span>,<span class="dv">1</span>))</span>
<span id="cb5-3"><a href="#cb5-3" tabindex="-1"></a><span class="co">#&gt; $`Sample size`</span></span>
<span id="cb5-4"><a href="#cb5-4" tabindex="-1"></a><span class="co">#&gt;                                            Stage 1 Stage 2 Stage 3</span></span>
<span id="cb5-5"><a href="#cb5-5" tabindex="-1"></a><span class="co">#&gt; Cumulative sample size for treatment group      21      42      62</span></span>
<span id="cb5-6"><a href="#cb5-6" tabindex="-1"></a><span class="co">#&gt; Cumulative sample size for control group        21      42      62</span></span>
<span id="cb5-7"><a href="#cb5-7" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb5-8"><a href="#cb5-8" tabindex="-1"></a><span class="co">#&gt; $`Maximum total sample size for the trial`</span></span>
<span id="cb5-9"><a href="#cb5-9" tabindex="-1"></a><span class="co">#&gt; [1] 310</span></span>
<span id="cb5-10"><a href="#cb5-10" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb5-11"><a href="#cb5-11" tabindex="-1"></a><span class="co">#&gt; $`Boundary values`</span></span>
<span id="cb5-12"><a href="#cb5-12" tabindex="-1"></a><span class="co">#&gt;             Stage 1 Stage 2 Stage 3</span></span>
<span id="cb5-13"><a href="#cb5-13" tabindex="-1"></a><span class="co">#&gt; Lower bound  -0.630   0.437   2.161</span></span>
<span id="cb5-14"><a href="#cb5-14" tabindex="-1"></a><span class="co">#&gt; Upper bound   3.126   3.092   2.161</span></span></code></pre></div>
<p>Based on the design parameters, the first interim analysis can be
conducted after the enrollment of 21 patients(information time is 21/62
which is approximately 1/3 at this stage) in the control and treatment
arms. If the test statistic <span class="math inline">\(Z_{k,l}&lt;-0.63\)</span>, the <span class="math inline">\(k_{th}\)</span> arm is rejected for futility at
<span class="math inline">\(1^{st}\)</span> stage and the trial
continues with the remaining treatment arms and the control. If the test
statistic -0.63 <span class="math inline">\(\le\)</span> <span class="math inline">\(Z_{k,l}\)</span> <span class="math inline">\(\le\)</span> 3.126 for <span class="math inline">\(k\)</span>=1,2,3,4 then the trial continues to the
next stage and 21 patients are further enrolled per arm. If <span class="math inline">\(Z_{k,1} &gt;3.126\)</span> for some <span class="math inline">\(k\)</span>, the trial is terminated and the arm
with maximum value of <span class="math inline">\(Z_{k,1}\)</span>,
<span class="math inline">\(k\)</span>=1,2,3,4 would be recommend for
further study. Similar procedure is followed if the trial goes to second
stage of interim analysis.</p>
<p>The operating characteristics can be generated using the functions
op_fwer_ord and op_power_ord which are similar to that of continuous
outcome.</p>
</div>
<div id="survival-outcome" class="section level2">
<h2>Survival Outcome</h2>
<p>For survival outcome, we will consider a MAMS trial with five arms
(four treatment arms and a control arm, K=4) and two interim looks with
balanced information time (0.5, 1). The null hazards ratio is 1 and the
alternative hazards ratio is 0.65. The median survival time of control
group is 20 months and the survival distribution is exponential without
loss to follow-up. The sample size calculation is based on a one-sided
type I error of 5% and a power of 90%.</p>
<p>The design parameters for a two-stage design can be calculated using
the design_surv function and the arguments in the function correspond to
median survival time of the control group(m0), hazard ratio of
ineffective treatment vs control(HR0), hazard ratio of effective
treatment vs control(HR1), accrual time(ta), follow-up time(tf), shape
parameter of Weibull distribution(kappa), rate of loss to
follow-up(eta)(assumed loss to follow-up follows an exponential
distribution with rate parameter eta).</p>
<div class="sourceCode" id="cb6"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" tabindex="-1"></a><span class="fu">design_surv</span>(<span class="at">m0=</span><span class="dv">20</span>,<span class="at">hr0=</span><span class="dv">1</span>, <span class="at">hr1=</span><span class="fl">0.67032</span>, <span class="at">ta=</span><span class="dv">40</span>,<span class="at">tf=</span><span class="dv">20</span>,<span class="at">alpha=</span><span class="fl">0.05</span>,<span class="at">beta=</span><span class="fl">0.1</span>,</span>
<span id="cb6-2"><a href="#cb6-2" tabindex="-1"></a><span class="at">k=</span><span class="dv">4</span>,<span class="at">kappa=</span><span class="dv">1</span>,<span class="at">eta=</span><span class="dv">0</span>,<span class="at">frac=</span><span class="fu">c</span>(<span class="fl">0.5</span>,<span class="dv">1</span>))</span>
<span id="cb6-3"><a href="#cb6-3" tabindex="-1"></a><span class="co">#&gt; $`Sample size`</span></span>
<span id="cb6-4"><a href="#cb6-4" tabindex="-1"></a><span class="co">#&gt;                                                              Stage 1 Stage 2</span></span>
<span id="cb6-5"><a href="#cb6-5" tabindex="-1"></a><span class="co">#&gt; Cumulative number of events for combined treatment &amp; control     164     328</span></span>
<span id="cb6-6"><a href="#cb6-6" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb6-7"><a href="#cb6-7" tabindex="-1"></a><span class="co">#&gt; $`Maximum total number of events for the trial`</span></span>
<span id="cb6-8"><a href="#cb6-8" tabindex="-1"></a><span class="co">#&gt; [1] 820</span></span>
<span id="cb6-9"><a href="#cb6-9" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb6-10"><a href="#cb6-10" tabindex="-1"></a><span class="co">#&gt; $`Total number of subjects required for the trial`</span></span>
<span id="cb6-11"><a href="#cb6-11" tabindex="-1"></a><span class="co">#&gt; [1] 1170</span></span>
<span id="cb6-12"><a href="#cb6-12" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb6-13"><a href="#cb6-13" tabindex="-1"></a><span class="co">#&gt; $`Boundary values`</span></span>
<span id="cb6-14"><a href="#cb6-14" tabindex="-1"></a><span class="co">#&gt;             Stage 1 Stage 2</span></span>
<span id="cb6-15"><a href="#cb6-15" tabindex="-1"></a><span class="co">#&gt; Lower bound   0.075    2.16</span></span>
<span id="cb6-16"><a href="#cb6-16" tabindex="-1"></a><span class="co">#&gt; Upper bound   2.980    2.16</span></span></code></pre></div>
<p>The design output shows the cumulative number of events for treatment
and control groups combined at each stage along with the futility and
efficacy boundaries. The total number of subjects required for the trial
per arm is 234. Based on the design parameters, the first interim
analysis can be conducted after the incidence of 164 events (information
time is 164/328 which is 0.5 at this stage) which results from the
aggregation of events in the control and treatment arms. If the test
statistic <span class="math inline">\(Z_{k,l}&lt;0.075\)</span>, the
<span class="math inline">\(k_{th}\)</span> arm is rejected for futility
at <span class="math inline">\(1^{st}\)</span> stage and the trial
continues with the remaining treatment arms and the control. If the test
statistic 0.075 <span class="math inline">\(\le\)</span> <span class="math inline">\(Z_{k,l}\)</span> <span class="math inline">\(\le\)</span> 2.98 for <span class="math inline">\(k\)</span>=1,2,3,4 then the trial continues to the
next stage and we will wait for the incidence of additional 164 events
to conduct the next interim analysis. If <span class="math inline">\(Z_{k,1} &gt;2.98\)</span> for some <span class="math inline">\(k\)</span>, the trial is terminated and the arm
with maximum value of <span class="math inline">\(Z_{k,1}\)</span>,
<span class="math inline">\(k\)</span>=1,2,3,4 would be recommend for
further study.</p>
<p>The operating characteristics of the trial can be generated using the
op_power_surv and op_fwer_surv function.</p>
<p>For FWER and Stagewise FWER:</p>
<div class="sourceCode" id="cb7"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" tabindex="-1"></a><span class="fu">op_fwer_surv</span>(<span class="at">m0=</span><span class="dv">20</span>,<span class="at">alpha=</span><span class="fl">0.05</span>,<span class="at">beta=</span><span class="fl">0.1</span>,<span class="at">p=</span><span class="dv">4</span>,<span class="at">frac=</span><span class="fu">c</span>(<span class="dv">1</span><span class="sc">/</span><span class="dv">2</span>,<span class="dv">1</span>),<span class="at">hr0=</span><span class="dv">1</span>,<span class="at">hr1=</span><span class="fl">0.6703</span>,</span>
<span id="cb7-2"><a href="#cb7-2" tabindex="-1"></a><span class="at">nsim=</span><span class="dv">10000</span>,<span class="at">ta=</span><span class="dv">40</span>,<span class="at">tf=</span><span class="dv">20</span>,<span class="at">kappa=</span><span class="dv">1</span>,<span class="at">eta=</span><span class="dv">0</span>,<span class="at">seed=</span><span class="dv">12</span>)</span>
<span id="cb7-3"><a href="#cb7-3" tabindex="-1"></a><span class="co">#&gt; $FWER</span></span>
<span id="cb7-4"><a href="#cb7-4" tabindex="-1"></a><span class="co">#&gt; [1] 0.05</span></span>
<span id="cb7-5"><a href="#cb7-5" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb7-6"><a href="#cb7-6" tabindex="-1"></a><span class="co">#&gt; $`Stagewise FWER`</span></span>
<span id="cb7-7"><a href="#cb7-7" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb7-8"><a href="#cb7-8" tabindex="-1"></a><span class="co">#&gt; 0.0049 0.0460 </span></span>
<span id="cb7-9"><a href="#cb7-9" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb7-10"><a href="#cb7-10" tabindex="-1"></a><span class="co">#&gt; $`Stopping probability under null`</span></span>
<span id="cb7-11"><a href="#cb7-11" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb7-12"><a href="#cb7-12" tabindex="-1"></a><span class="co">#&gt; 0.2318 0.7682 </span></span>
<span id="cb7-13"><a href="#cb7-13" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb7-14"><a href="#cb7-14" tabindex="-1"></a><span class="co">#&gt; $`Probability of futility under null`</span></span>
<span id="cb7-15"><a href="#cb7-15" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb7-16"><a href="#cb7-16" tabindex="-1"></a><span class="co">#&gt; 0.2269 0.7234 </span></span>
<span id="cb7-17"><a href="#cb7-17" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb7-18"><a href="#cb7-18" tabindex="-1"></a><span class="co">#&gt; $`Average number of events happened per arm under null`</span></span>
<span id="cb7-19"><a href="#cb7-19" tabindex="-1"></a><span class="co">#&gt; [1] 129.5902</span></span>
<span id="cb7-20"><a href="#cb7-20" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb7-21"><a href="#cb7-21" tabindex="-1"></a><span class="co">#&gt; $`Average duration of trial(months)`</span></span>
<span id="cb7-22"><a href="#cb7-22" tabindex="-1"></a><span class="co">#&gt; [1] 54.27148</span></span></code></pre></div>
<p>Based on the simulation results, the type I error is around 0.4% at
first interim analysis and around 4.6% at the second interim analysis.
Therefore, the overall type I error is maintained at 5%. The stopping
probability should be around 1 which is the case here and since this is
under null configuration, probability of futility should be around 95%
which holds true in this case. The average duration of trial is 54
months which is reasonable as the total duration of the trial is 60
months. The average number of events happened per arm is 130.</p>
<p>For Power and Stagewise Power :</p>
<div class="sourceCode" id="cb8"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" tabindex="-1"></a><span class="fu">op_power_surv</span>(<span class="at">m0=</span><span class="dv">20</span>,<span class="at">alpha=</span><span class="fl">0.05</span>,<span class="at">beta=</span><span class="fl">0.1</span>,<span class="at">p=</span><span class="dv">4</span>,<span class="at">frac=</span><span class="fu">c</span>(<span class="dv">1</span><span class="sc">/</span><span class="dv">2</span>,<span class="dv">1</span>),<span class="at">hr0=</span><span class="dv">1</span>,<span class="at">hr1=</span>.<span class="dv">6703</span>,</span>
<span id="cb8-2"><a href="#cb8-2" tabindex="-1"></a><span class="at">nsim=</span><span class="dv">10000</span>,<span class="at">ta=</span><span class="dv">40</span>,<span class="at">tf=</span><span class="dv">20</span>,<span class="at">kappa=</span><span class="dv">1</span>,<span class="at">eta=</span><span class="dv">0</span>,<span class="at">seed=</span><span class="dv">12</span>)      </span>
<span id="cb8-3"><a href="#cb8-3" tabindex="-1"></a><span class="co">#&gt; $Power</span></span>
<span id="cb8-4"><a href="#cb8-4" tabindex="-1"></a><span class="co">#&gt; [1] 0.913</span></span>
<span id="cb8-5"><a href="#cb8-5" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb8-6"><a href="#cb8-6" tabindex="-1"></a><span class="co">#&gt; $`Stagewise Power`</span></span>
<span id="cb8-7"><a href="#cb8-7" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb8-8"><a href="#cb8-8" tabindex="-1"></a><span class="co">#&gt; 0.3270 0.5863 </span></span>
<span id="cb8-9"><a href="#cb8-9" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb8-10"><a href="#cb8-10" tabindex="-1"></a><span class="co">#&gt; $`Stopping probability under alternative`</span></span>
<span id="cb8-11"><a href="#cb8-11" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb8-12"><a href="#cb8-12" tabindex="-1"></a><span class="co">#&gt; 0.3334 0.6666 </span></span>
<span id="cb8-13"><a href="#cb8-13" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb8-14"><a href="#cb8-14" tabindex="-1"></a><span class="co">#&gt; $`Probability of futility under alternative`</span></span>
<span id="cb8-15"><a href="#cb8-15" tabindex="-1"></a><span class="co">#&gt;  look1  look2 </span></span>
<span id="cb8-16"><a href="#cb8-16" tabindex="-1"></a><span class="co">#&gt; 0.0059 0.0800 </span></span>
<span id="cb8-17"><a href="#cb8-17" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb8-18"><a href="#cb8-18" tabindex="-1"></a><span class="co">#&gt; $`Average number of events happened per arm under alternative`</span></span>
<span id="cb8-19"><a href="#cb8-19" tabindex="-1"></a><span class="co">#&gt; [1] 115.0483</span></span>
<span id="cb8-20"><a href="#cb8-20" tabindex="-1"></a><span class="co">#&gt; </span></span>
<span id="cb8-21"><a href="#cb8-21" tabindex="-1"></a><span class="co">#&gt; $`Average duration of trial(months)`</span></span>
<span id="cb8-22"><a href="#cb8-22" tabindex="-1"></a><span class="co">#&gt; [1] 52.27229</span></span></code></pre></div>
<p>Based on the simulation results, the probability of success/power at
the first stage is 32.7% and at the second stage is around 58.63%.
Therefore, the overall power is around 90%. The overall stopping
probability should be around 1 which is the case here and the
probability of futility is around 8.5% which is less than 10% type II
error because of the same reason as mentioned in the continuous outcome.
The average duration of trial is 52 months which is reasonable as the
total duration of the trial is 60 months. The average number of events
happened per arm is 115.</p>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
